Search | Clinical Trials Finder

Conditions: Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage IVC Colorectal Cancer, Colorectal Cancer Metastatic
Interventions: Metformin, Nivolumab; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: Vildagliptin, metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions: Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo; Drug
Lead sponsor: Kalie Tommerdahl; Other
Eligibility: 12 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 44
States / cities: Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more

Conditions: Atrial Fibrillation
Interventions: Metformin; Drug
Lead sponsor: The Guthrie Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Sayre, Pennsylvania

Conditions: Prostate Cancer
Interventions: Placebo, Metformin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus
Interventions: Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Obesity, Metabolic Syndrome X
Interventions: Metformin, Orlistat, Topiramate, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 40 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin aspart, liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 48
States / cities: Concord, California • La Jolla, California • Lancaster, California + 44 more

Conditions: Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes
Interventions: Insulin, Glyburide, Metformin; Drug
Lead sponsor: Maisa N. Feghali, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gestational Diabetes Mellitus
Interventions: Glyburide, Metformin, Glyburide-Metformin combination; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Dietary Restriction, Exercise Training; Drug · Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Adenocarcinoma
Interventions: Paclitaxel, Carboplatin, Bevacizumab, Metformin; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type II
Interventions: Dutogliptin, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 98
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 84 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Empagliflozin, Metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions: Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent; Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Oral Leukoplakia
Interventions: pioglitazone-metformin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Canakinumab, Metformin, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, BI 10773 Placebo, BI 10773 / BI 1356, BI 10773 / BI 1356 Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 24
States / cities: Chino, California • Huntington Beach, California • San Diego, California + 20 more

Conditions: Breast Cancer, Solid Tumors, Adult
Interventions: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more

Conditions: Type 2 Diabetes
Interventions: SLx-4090, Placebo, Metformin; Drug · Other
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Anaheim, California • Burbank, California • Los Angeles, California + 8 more

Conditions: Prediabetic State, Atherosclerosis, Metformin
Interventions: Metformin XR, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 7,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Breast Cancer Stage, Insulin Resistance, Racial Bias
Interventions: Metformin Extended Release Oral Tablet; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 80 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Search by objective public record fields.

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Metformin as an Upstream Therapy in Atrial Fibrillation

Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer

Oral Anti Diabetic Agents in the Hospital

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus

Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)

Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS

Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Truway Diagnostic Tools in Primary Care

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer